H1N1 VLP triple antigen vaccine

The H1N1 VLP triple antigen vaccine is a type of virus-like particle (VLP) vaccine designed to protect against influenza. VLPs are self-assembling protein structures that mimic the external shape of a virus but do not contain any genetic material, rendering them non-infectious. This vaccine presents key viral antigens, such as hemagglutinin (HA) and neuraminidase (NA), from three different influenza strains (H1N1, H3N2, and B) to the immune system. By doing so, it stimulates the body to produce a robust immune response, including antibodies, without causing an actual infection. This approach aims to provide protection against seasonal and potentially pandemic influenza by targeting multiple prevalent strains. Developers like Medicago and Novavax have explored VLP technology for influenza vaccines, with Medicago developing a plant-based H1N1 VLP vaccine and Novavax utilizing insect cells and baculovirus expression systems for their VLP vaccine candidates.